Trial Profile
An Open-Label, Multicenter, Randomized Phase Ib/II Study of FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs E 7820 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions
- 11 Oct 2023 Status changed from completed to discontinued.
- 05 Apr 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 08 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.